Nothing Special   »   [go: up one dir, main page]

PE20231743A1 - Proceso e intermediarios para preparar un inhibidor de jak - Google Patents

Proceso e intermediarios para preparar un inhibidor de jak

Info

Publication number
PE20231743A1
PE20231743A1 PE2023000317A PE2023000317A PE20231743A1 PE 20231743 A1 PE20231743 A1 PE 20231743A1 PE 2023000317 A PE2023000317 A PE 2023000317A PE 2023000317 A PE2023000317 A PE 2023000317A PE 20231743 A1 PE20231743 A1 PE 20231743A1
Authority
PE
Peru
Prior art keywords
intermediaries
prepare
jak inhibitor
ruxolitinib
jak
Prior art date
Application number
PE2023000317A
Other languages
English (en)
Inventor
Jiacheng Zhou
Shili Chen
Pingli Liu
David J Meloni
James M Parks
Yongchun Pan
Naijing Su
Michael Xia
Weiguo Liu
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20231743A1 publication Critical patent/PE20231743A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/31—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invencion se relaciona con procesos para preparar ruxolitinib, o una sal de este, e intermediarios relacionados sinteticos asociados a estos. Ruxolitinib y sus sales son utiles como inhibidores de la familia Janus Kinase de proteinas tirosina quinasas (JAK) para el tratamiento de enfermedades inflamatorias, trastornos mieloproliferativos y otras enfermedades.
PE2023000317A 2020-08-18 2021-08-17 Proceso e intermediarios para preparar un inhibidor de jak PE20231743A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063067097P 2020-08-18 2020-08-18
US202163214012P 2021-06-23 2021-06-23
US202163217498P 2021-07-01 2021-07-01
PCT/US2021/046298 WO2022040180A1 (en) 2020-08-18 2021-08-17 Process and intermediates for preparing a jak inhibitor

Publications (1)

Publication Number Publication Date
PE20231743A1 true PE20231743A1 (es) 2023-10-31

Family

ID=77655708

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000317A PE20231743A1 (es) 2020-08-18 2021-08-17 Proceso e intermediarios para preparar un inhibidor de jak

Country Status (16)

Country Link
US (2) US11905292B2 (es)
EP (1) EP4200300A1 (es)
JP (1) JP2023539126A (es)
KR (1) KR20230096973A (es)
AU (1) AU2021329303A1 (es)
CA (1) CA3192099A1 (es)
CL (1) CL2023000480A1 (es)
CO (1) CO2023003281A2 (es)
CR (1) CR20230129A (es)
DO (1) DOP2023000035A (es)
EC (1) ECSP23019417A (es)
IL (1) IL300555A (es)
MX (1) MX2023002037A (es)
PE (1) PE20231743A1 (es)
TW (1) TW202227448A (es)
WO (1) WO2022040180A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123268A1 (es) 2020-08-18 2022-11-16 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak1
JP2024526762A (ja) 2021-07-12 2024-07-19 インサイト・コーポレイション Ｊａｋ阻害剤を調製するためのプロセス及び中間体
CN115850115B (zh) * 2022-11-25 2023-08-01 上海药坦药物研究开发有限公司 鲁索利替尼中间体及其制备方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB812366A (en) 1955-08-18 1959-04-22 Wellcome Found Improvements in and relating to derivatives of pyrimidine and the preparation thereof
US5102904A (en) 1989-12-08 1992-04-07 American Cyanamid Company N-oxygenated arylpyrrole insecticidal, acaricidal and nematicidal agents and use thereas
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
CA2566160C (en) 2004-05-27 2011-01-18 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
NZ565363A (en) 2005-07-29 2010-03-26 Pfizer Prod Inc Pyrrolo[2,3-D]pyrimidine derivatives; their intermediates and synthesis
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
CN2928286Y (zh) 2006-01-06 2007-08-01 水城钢铁（集团）有限责任公司 预入口导卫装置
KR101450535B1 (ko) 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
KR20100038119A (ko) 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
BRPI0820544A2 (pt) 2007-11-16 2015-06-16 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
CN102026999B (zh) 2008-03-11 2014-03-05 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CA2756250A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
UA106078C2 (uk) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
EA201290210A1 (ru) 2009-11-06 2012-10-30 Плексксикон, Инк. Соединения и способы модуляции киназы и показания для их применения
NZ599872A (en) 2009-11-18 2014-08-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EA023444B1 (ru) 2010-02-18 2016-06-30 Инсайт Холдингс Корпорейшн Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения
EA030376B1 (ru) 2010-03-10 2018-07-31 Инсайт Холдингс Корпорейшн Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
KR101921466B1 (ko) 2010-05-21 2018-11-26 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
KR20140019300A (ko) 2010-11-19 2014-02-14 인사이트 코포레이션 Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
CN105001226B (zh) 2011-08-12 2017-09-08 日产化学工业株式会社 三环杂环化合物和jak抑制剂
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
SG10202111768XA (en) 2012-11-15 2021-11-29 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
TR201820520T4 (tr) 2013-03-06 2019-01-21 Incyte Holdings Corp Bir jak inhibitörü yapmaya yönelik prosesler ve ara ürünler.
EA036448B1 (ru) 2013-05-17 2020-11-11 Инсайт Корпорейшн Производные бипиразола в качестве ингибиторов jak
HUE049345T2 (hu) 2013-08-07 2020-09-28 Incyte Corp Nyújtott hatóanyag-leadású dózisformák JAK1 inhibitorhoz
CN106687462A (zh) 2014-04-30 2017-05-17 因赛特公司 Jak1抑制剂的制备方法以及其新形式
ES2874537T3 (es) 2014-08-21 2021-11-05 Ratiopharm Gmbh Sal oxalato de ruxolitinib
EP3183253B1 (en) 2014-08-21 2018-06-27 ratiopharm GmbH Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid
WO2016035014A1 (en) 2014-09-01 2016-03-10 Sun Pharmaceutical Industries Limited Processes for the preparation of ruxolitinib phosphate
WO2016063294A2 (en) 2014-10-20 2016-04-28 Msn Laboratories Private Limited Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof
CN107278205A (zh) 2015-02-24 2017-10-20 辉瑞大药厂 用作抗癌药的取代的核苷衍生物
CN106397443A (zh) 2015-07-17 2017-02-15 浙江九洲药业股份有限公司 一种吡咯嘧啶类衍生物中间体的制备方法
CZ2015575A3 (cs) 2015-08-26 2017-03-08 Zentiva, K.S. Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava
WO2017106957A1 (en) 2015-12-23 2017-06-29 The University Of British Columbia Lipid-linked prodrugs
JP6921087B2 (ja) 2015-12-31 2021-08-18 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. ルキソリチニブの合成プロセス
CZ201629A3 (cs) 2016-01-22 2017-08-02 Zentiva, K.S. Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy
CN107513069A (zh) 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
IN201641026603A (es) 2016-08-04 2018-02-09
CN107722012B (zh) 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
CN107759601B (zh) 2016-08-23 2020-09-11 苏州旺山旺水生物医药有限公司 一种jak抑制剂及其盐的制备方法
CN107759623B (zh) 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
JP2019532944A (ja) 2016-09-23 2019-11-14 セルイプセ Ｌｉｍｋ介在性疾患における、ｌｉｍキナーゼ阻害剤、医薬組成物および使用方法
CN109651424B (zh) 2017-10-11 2021-01-22 新发药业有限公司 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
RS63312B1 (sr) 2018-01-30 2022-07-29 Incyte Corp Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on)
PT3797099T (pt) 2018-05-21 2024-02-05 Pi Industries Ltd Método para preparar compostos heterocíclicos substituídos
CN113906032A (zh) 2019-02-06 2022-01-07 康塞特医药品有限公司 用于制备对映异构体富集的jak抑制剂的方法
CN110724145A (zh) 2019-11-01 2020-01-24 廖文杰 一种医药中间体4-氯吡咯并嘧啶的合成方法
AR123268A1 (es) 2020-08-18 2022-11-16 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak1
JP2024526762A (ja) 2021-07-12 2024-07-19 インサイト・コーポレイション Ｊａｋ阻害剤を調製するためのプロセス及び中間体
CN113480546A (zh) 2021-07-30 2021-10-08 江苏君若药业有限公司 巴瑞克替尼及其衍生物的制备

Also Published As

Publication number Publication date
CO2023003281A2 (es) 2023-06-30
WO2022040180A1 (en) 2022-02-24
IL300555A (en) 2023-04-01
EP4200300A1 (en) 2023-06-28
US20220056035A1 (en) 2022-02-24
CR20230129A (es) 2023-07-13
JP2023539126A (ja) 2023-09-13
MX2023002037A (es) 2023-06-12
CL2023000480A1 (es) 2023-08-04
CA3192099A1 (en) 2022-02-24
DOP2023000035A (es) 2023-06-15
AU2021329303A1 (en) 2023-04-06
KR20230096973A (ko) 2023-06-30
US20240166655A1 (en) 2024-05-23
US11905292B2 (en) 2024-02-20
ECSP23019417A (es) 2023-04-28
TW202227448A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
PE20231743A1 (es) Proceso e intermediarios para preparar un inhibidor de jak
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
CU20180006A7 (es) Compuestos de indazaol y azaindazol como inhibidores de irak-4
CO2021008224A2 (es) Inhibidores de kif18a
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CU20210029A7 (es) Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades
CU20210094A7 (es) Inhibidores del inflamasoma nlrp3
CO2018010504A2 (es) Inhibidores del enlace proteína-proteína de wdr5
CU24643B1 (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
ECSP20023795A (es) Compuesto de pirimidina como inhibidor de las janocinasas
MY200629A (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
CO2021002225A2 (es) Compuestos heteroaromáticos como inhibidores de vanina
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CO2020000371A2 (es) Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos
CO2019013823A2 (es) Compuestos heteroaromáticos como inhibidores de vanina
ECSP23019419A (es) Proceso e intermedios para preparar un inhibidor de jak1
CO2023009368A2 (es) Cocristal de un inhibidor de cdk
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
CO2020000595A2 (es) Intermedios novedosos útiles para la síntesis de derivados de aminopirimidina, proceso para prepararlos, y proceso para preparar derivados de aminopirimidina usando estos
EA202090393A1 (ru) Терапевтическое средство от фиброза